CALR and myeloproliferative neoplasm: Further acquired abnormalities in MPN were the discovery of mutations in the thrombopoietin receptor (MPL) [8] in 2006 and calreticulin (CALR) in 2013, further revolutionising our understanding, diagnostic classification, treatment and prognosis of MPNs [9, 10].